Lilly's Cancer Group Still Committed to PGx Despite Higher Cost Than Originally Expected | GenomeWeb
LOS ANGELES — Although biomarker-based PGx studies cost more and are more complex than traditional clinical trials at Eli Lilly, the drug maker has made pharmacogenomics an integral part of its overall R&D strategy, according to one Lilly official.
 
Lilly’s experience goes against conventional wisdom that predictive technologies would reduce the cost of drug development by enabling smaller clinical trials and by lowering drug attrition in late-stage studies.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.